This page shows the latest escitalopram news and features for those working in and with pharma, biotech and healthcare.
protection for Abilify and former blockbuster antidepressant Lexapro/Celexa (escitalopram).
Since its former blockbuster Cipralex (escitalopram) started to succumb to generic competition, Lundbeck has looked to two newer antidepressants - Brintellix/Trintellix (vortioxetine) and Rexulti (brexpiprazole) - to step in and fill the
sales from drugs such as depression treatment Cipralex (escitalopram).
Brintellix has been on the market in the US since 2013 and has been positioned as a successor to its older antidepressant Cipralex (escitalopram), which was selling around $2bn a year
which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).
to continued generic competition to Alzheimer's therapy Ebixa (memantine) and antidepressant Cipralex (escitalopram).
More from news
Approximately 5 fully matching, plus 48 partially matching documents found.